BioMarin Pharma (BMRN) Tops Q1 EPS by 46c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
EPS Growth %: +1,016.7%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Provision for income taxes: -24.02M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.63, $0.46 better than the analyst estimate of $0.17. Revenue for the quarter came in at $519 million versus the consensus estimate of $507.52 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- lululemon athletica (LULU) Tops Q2 EPS by $1.10, Cuts Guidance
- Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
